‘We bring regenerative therapies to the masses in the most cost-effective way possible’: Dr. David Greene, CEO of R3 Stem Cell

Living with chronic pain can disrupt your life and make it impossible for you to do your job, play with your kids, or remain independent. Today, thanks to the exciting and rapidly evolving advances in regenerative medicine, chronic pain management isn’t only about managing pain — it’s about healing damaged tissues at the cellular level and restoring pain-free mobility from the inside out. Innovative new regenerative medicine treatments can help restore your quality of life — without major surgery.

R3 Stem Cell is one such US-based company that pioneers in innovative regenerative medicine, offering therapies that harness the body’s regenerative capabilities to bring patients hope and options. It is the only company in the US to have achieved Institutional Review Board Approval for the investigation of regenerative therapies with amniotic and umbilical cord tissue for several condition categories.

Dr. David Greene, CEO of R3 Stem Cell, spoke exclusively to CIO Bulletin about the ever-expanding field of regenerative medicine and what makes R3 Stem Cell the industry leaders.

Interview Highlights

Q. What inspired you to found R3 Stem Cell in the contemporary scientific environment, where alternative forms are dismissed with cynicism?

When I created R3 Stem Cell, it was initially a fake company for my Entrepreneurial Class at ASU Business School. But the feedback I received from the ASU professors was so overwhelmingly positive that I decided to make it a real company. I knew all too well that new technology is dismissed outright by a large part of the medical community, but regenerative therapies are only becoming more popular globally. Healthcare providers can either get onboard or watch the opportunity pass them by!

Q. How have patients reacted to your approach to treatment? Can you briefly describe stem cell therapy and the various stem cell treatments that R3 Stem Cell provides?

Over the past decade, our global footprint has continued to expand tremendously. We now have over 40 Centers in six countries and growing! Patient satisfaction is 85% year after year, and we keep developing best practice protocols to obtain better results.

The treatments we offer are varied and customized for patients. They include autologous adipose stem cell therapy, platelet rich plasma therapy, and umbilical cord stem cell therapies. These are offered through different means internationally, such as injection, intravenous, nebulizer, intrathecal, and intranasal.

Q. How has the company changed since it was first established?

When I first started R3 Stem Cell, it was solely a USA company. Over the years, we have developed a presence in six countries and have been able to help over 20,000 patients. With our significant volume, we’ve developed into the most cost-effective regenerative therapy Centers in the world!

Q. What were some of the difficulties the company faced? What conclusions has the company drawn from resolving them?

One of the biggest difficulties we’ve faced has been misinformation being disseminated by competitors. It has been very unfortunate, as there are so many unscrupulous individuals in the industry who twist facts to suit their own narrative.

So what we have accomplished over the past ten years has involved extensive education with accurate information to help consumers make more informed decisions. I stay away from publishing inaccurate information and mudslinging, because business shouldn’t be ethically conducted in that manner!

Q. What ethical standards does the company adhere to when treating its clients?

The main ethical standard is that our providers don’t offer ANY regenerative therapies that they wouldn’t do themselves or recommend to friends and family. In fact, most of our staff have received regenerative therapies and have benefited tremendously!

In addition, I made the decision years ago to bring regenerative therapies to the masses in the most cost effective way possible. Too many clinics charge two to three times what we do and think that’s acceptable. It shouldn’t just be for the wealthy!

Q. Which patients can receive care from R3 Stem Cell? Are there any restrictions on how  stem cells can be used?

There are a few restrictions with our stem cell therapies. For instance, those undergoing active cancer treatment are excluded, along with those who are pregnant or have an active infection.

Our clinics internationally treat over 50 conditions such as diabetes, stroke, autism, arthritis, and kidney failure. At times, our providers will deem a person not to be a candidate depending on what the lab studies show. When a person is deemed to be a candidate, we will customize the amount of stem cells and the type of application.

Q. Do you want us to bring your attention to something significant going on in your company that we may have overlooked?

R3 Stem Cell has expanded over the years into provider training with R3 Medical Training. We offer hands-on courses with live patients that are CME-accredited. Providers are able to learn and cement a skillset for regenerative therapies, MSK ultrasound injections, and aesthetic procedures such as hair restoration, PDO threads, and sexual health.